Revolutionizing Breast Imaging: ScreenPoint Medical Unveils Transpara AI Suite at RSNA 2025

Transforming Breast Imaging with Transpara

At the 111th Annual Radiological Society of North America (RSNA) meeting in Chicago, ScreenPoint Medical introduced its innovative Transpara Breast AI suite, a comprehensive solution aimed at improving breast cancer detection and streamlining radiologist workflows. Running from November 30 to December 4, 2025, this event marks a significant moment in advancing the use of artificial intelligence in healthcare.

Transpara Breast AI is distinguished as the most clinically validated AI solution available today, offering capabilities in Detection, Density, and Temporal Comparison. The suite serves as a supportive tool, providing radiologists with an additional layer of scrutiny to identify breast cancer at earlier stages, decrease their workload, and enhance overall performance within healthcare programs.

This year has proven to be monumental for ScreenPoint Medical, having surpassed the impressive milestone of processing over 11 million mammograms. The technology is now deployed across 30 countries, trusted by notable healthcare institutions, including 40% of the Top 20 hospitals recognized by U.S. News and World Report.

A crucial component of the Transpara suite is its involvement in pivotal randomized controlled trials (RCTs) such as the MASAI RCT in Sweden and the upcoming $16 million PRISM RCT in the United States, slated to begin in early 2026. Insights from the MASAI study revealed a staggering 29% increase in cancer detection rates and a 44% reduction in the reading workload for radiologists using Transpara Detection compared to traditional methods.

Focus on Risk Assessment

The significance of risk assessment is a central theme at this year's RSNA, showcased through Transpara Risk, an image-based model that predicts the five-year breast cancer risk. A notable study presented at the conference, titled "Added Value of Breast Cancer Risk Prediction Versus Detection Over a Two-Year Period with Mammography," illustrated how Transpara’s solutions surpass both existing CAD systems and Mirai, affirming their commitment to empowering women by providing personalized care pathways and facilitating early diagnoses for less aggressive treatments. Please note that Transpara Risk is currently approved for investigational use only.

Throughout the week, multiple presentations and posters outlined the clinical and operational advantages offered by the Transpara Breast AI. A groundbreaking study titled "Comparing Four Commercial AI Algorithms for Standalone Breast Cancer Detection on Digital Breast Tomosynthesis" marked the first instance of evaluating commercial AI algorithms on a substantial dataset, with Transpara Detection emerging as the frontrunner in performance.

Additionally, posters such as "Potential of Artificial Intelligence to Detect Interval Breast Cancers" suggested that Transpara Detection could have contributed to the earlier detection of 38% of interval breast cancers often overlooked by radiologists, bolstering the research conducted at Johns Hopkins Medicine.

Other noteworthy studies, including evaluations of AI performance based on prior examinations and the practical application of Transpara in busy mammography settings, further solidified the efficacy of this advanced AI tool. For instance, a study on AI pre-reading of Digital Breast Tomosynthesis showcased a novel AI-driven imaging biomarker, achieving nearly a 100% negative predictive value in identifying normal examinations, showing promising potential for accelerating radiologist efficiency.

Vision for the Future

ScreenPoint Medical’s CEO, Pieter Kroese, emphasized the transformative impact of their technology, stating, "We believe that research drives real-world results. The groundbreaking research presented at RSNA 2025 affirms that Transpara Breast AI is not just advancing technology, but setting a new standard in patient care." With a focus on collaboration and innovation, ScreenPoint Medical aims to lead in the breast health sector, striving for excellence in every facet of the breast imaging continuum.

For further insights into these leading Breast AI solutions, interested attendees can visit ScreenPoint Medical at Booth #4719 in the South Hall during RSNA 2025 or schedule an online product overview on their website. Together, through diligent research and technological advancement, ScreenPoint Medical is dedicated to transforming breast health and improving patient outcomes across the globe.